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1. INTRODUCTION {#mgg31200-sec-0005}
===============

The morbidity of cervical cancer is the fourth malignant disease of women, and the mortality of cervical cancer is also the fourth in the women\'s malignancies. Moreover, the incidence of young female of cervical cancer increased in recent decades. Statistics showed that the number of deaths worldwide in 2018 was 311,000 (Bray et al., [2018](#mgg31200-bib-0006){ref-type="ref"}). The total payments on cervix uteri and corpus uteri cancer treatments in China were estimated to be 11.5 billion RMB in 2015 (Li et al., [2017](#mgg31200-bib-0028){ref-type="ref"}). With the popularization of cervical cancer screening and the application of HPV vaccine, most patients are diagnosed and treated at early stage. However, the effect of treatment about advanced or recurrent cervical cancer is not significant, and targeted treatment for specific gene mutations may be a new trend. With the application and development of high‐throughput sequencing, gene chip in research of tumor genomics, it is significant to find the mechanism, prognostic factors, and potential therapeutic targets of cervical cancer. Some studies have reported that mutations of *FOXP3* (Cezar‐Dos‐Santos et al., [2019](#mgg31200-bib-0008){ref-type="ref"}), *PIK3CA* (Razia et al., [2019](#mgg31200-bib-0037){ref-type="ref"}), *XRCC4* (Gupta, Kushwah, Singh, & Banerjee, [2019](#mgg31200-bib-0020){ref-type="ref"}), *FBXW7* (Liu et al., [2019](#mgg31200-bib-0031){ref-type="ref"}), and some copy number variations of *KLF10* and *PSG* (Marrero‐Rodriguez et al., [2018](#mgg31200-bib-0034){ref-type="ref"}) are related to the carcinogenesis and pathogenesis of cervical cancer, but they were not complete so that to be further studied. This study aim to better understand the characteristics of some genes and signaling pathways that associate with cervical cancer through bioinformatics.

2. MATERIALS AND METHODS {#mgg31200-sec-0006}
========================

2.1. Microarray data {#mgg31200-sec-0007}
--------------------

We downloaded three gene expression profiles ([GSE63514](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63514) (den Boon et al., [2015](#mgg31200-bib-0011){ref-type="ref"}), [GSE6791](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6791) (Pyeon et al., [2007](#mgg31200-bib-0036){ref-type="ref"}), and [GSE9750](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9750) (Scotto et al., [2008](#mgg31200-bib-0041){ref-type="ref"})) from the gene expression omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo>) (Edgar, Domrachev, & Lash, [2002](#mgg31200-bib-0013){ref-type="ref"}), which is one of the most comprehensive public gene expression data resources available today. [GSE63514](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63514) consists of 28 tumor samples and 24 normal cervical samples, and [GSE6791](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6791) includes 20 tumor samples and 8 normal cervical samples. The gene chip platform of these two datasets is GPL570 Affymetrix Human Genome U133 Plus 2.0 Array. Moreover, [GSE9750](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9750) analyzed 33 tumor samples and 24 normal cervical samples. The gene chip platform of [GSE9750](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9750) is the GPL96 Affymetrix Human Genome U133A Array.

2.2. Identification of DEGs {#mgg31200-sec-0008}
---------------------------

We identified the DEGs, differentially expressed genes (DEGs) between cervical cancer and normal tissues by GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>). GEO2R is a method which could obtain the DEGs between two gene expression profiles in the GEO database by using Bioconductor\'s GEOquery and limma R software packages (Barrett et al., [2013](#mgg31200-bib-0004){ref-type="ref"}). It was set to screen the DEGs by adjusted *p* value \<.01 and logFC (fold change) \>2, and we used the Venn diagram to find the overlapped DEGs.

2.3. GO and KEGG enrichment analysis {#mgg31200-sec-0009}
------------------------------------

The Database for Annotation, Visualization and Integrated Discovery (DAVID, <http://david.abcc.ncifcrf.gov/>) (version 6.8) (Huang da, Sherman, & Lempicki, [2009](#mgg31200-bib-0021){ref-type="ref"}) is a public online bioinformatic database which helps to identify the most significant enriched functional genes and biological pathways. To further analyze the DEGs, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed by using the DAVID online tool. GO analysis was used to annotate biological process (BP), cytological component (CC), and molecular function (MF) of genes (Ashburner et al., [2000](#mgg31200-bib-0003){ref-type="ref"}; The Gene Ontology Consortium, [2019](#mgg31200-bib-0048){ref-type="ref"}), and KEGG enrichment analysis was used to understand the relevant signaling pathways (Kanehisa & Sato, [2019](#mgg31200-bib-0022){ref-type="ref"}). *p* value \<.05 was considered to be statistically significant.

2.4. PPI network and key module analysis {#mgg31200-sec-0010}
----------------------------------------

We constructed the protein--protein interaction network (PPI) of DEGs by using Search Tool for the Retrieval of Interacting Genes (STRING; [http://string‐db.org/](http://string-db.org/)) (version 11.0) (Szklarczyk et al., [2019](#mgg31200-bib-0046){ref-type="ref"}) database based on the confidence scores. What\'s more, we further visualized the PPI by Cytoscape (version 3.7.0) (Shannon et al., [2003](#mgg31200-bib-0042){ref-type="ref"}). And the Molecular Complex Detection (MCODE) plugin in Cytoscape was used to filter the key modules in the network with degree cutoff = 2, node score cutoff = 0.2, k‐core = 2, and max. depth = 100.

2.5. Key genes screening and analysis {#mgg31200-sec-0011}
-------------------------------------

The genes with degree ≥10 in the network were identified as key genes, and the co‐expressed genes were analyzed by cBioPortal (<http://www.cbioportal.org>) (Cerami et al., [2012](#mgg31200-bib-0007){ref-type="ref"}; Gao et al., [2013](#mgg31200-bib-0016){ref-type="ref"}) online platform. Gene Expression Profiling Interactive Analysis (GEPAI; [http://gepia.cancer‐pku.cn](http://gepia.cancer-pku.cn)) (Tang et al., [2017](#mgg31200-bib-0047){ref-type="ref"}) is an interactive web application for gene expression analysis. We visualized the expression of key genes in cervical cancer tissues and normal tissues by box plots in GEPIA, and the overall survival analysis of key genes was also performed. Expression profiles of *CXCL8* in human cancers were analyzed by UALCAN (<http://ualcan.path.uab.edu/index.html>) (Chandrashekar et al., [2017](#mgg31200-bib-0009){ref-type="ref"}). Oncomine (<https://www.oncomine.org>) was used to analyze *CXCL8* overexpression in multiple datasets comparing cervical cancer with normal tissues. The protein expression of CXCL8 in cervical cancer and normal tissues was analyzed by the human protein atlas (HAP; <https://www.proteinatlas.org>) (version 19) (Uhlen et al., [2017](#mgg31200-bib-0051){ref-type="ref"}).

3. RESULTS {#mgg31200-sec-0012}
==========

3.1. Identification of DEGs {#mgg31200-sec-0013}
---------------------------

The DEGs of [GSE63514](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63514), [GSE6791](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6791), and [GSE9750](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9750) were obtained by using the GEO2R online analysis tool and we identified the intersection of the three profiles by Venn diagram (Figure [1](#mgg31200-fig-0001){ref-type="fig"}). Total 57 differential genes were detected, of which 26 were upregulated and 31 were downregulated (Table [1](#mgg31200-tbl-0001){ref-type="table"}).

![Venn diagram. Identification of the differentially expressed genes in the [GSE63514](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63514), [GSE6791](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6791), and [GSE9750](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9750) gene expression profile datasets. The three datasets showed an overlap of 57 genes. DEGs, Differentially expressed genes](MGG3-8-e1200-g001){#mgg31200-fig-0001}

###### 

Name of 57 differentially expressed genes

  Differentially expressed genes                                                        
  -------------------------------- --------- -------- ------- -------- -------- ------- ---------
  STAT1                            NUP62CL   TOP2A    HOXC6   DSG1     ENDOU    KRT4    ALOX12
  AURKA                            ISG15     DTL      MMP12   CWH43    UPK1A    CLIC3   PPP1R3C
  NEK2                             CXCL8     CDKN2A   SPP1    GREB1    BBOX1    KLK11   ESR1
  TYMS                             GINS1     FANCI    CEP55   CXCL14   GLTP     THSD4   PDGFD
  MCM2                             ECT2      ENO2     CDK1    CRCT1    EDN3     EREG    SPINK5
  IFI44L                           FN1       HELLS    SYCP2   KRT13    HOPX     IVL     SOSTDC1
  INHBA                            WDHD1                      CRNN     CRISP3   KPT1    MAL
                                                              DSC2     KRT2     IL1R2    
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3.2. GO enrichment and KEGG pathway enrichment {#mgg31200-sec-0014}
----------------------------------------------

In the GO analysis, the screened DEGs mainly participate in the biological process (BP) of G1/S transition of mitotic cell cycle, mitotic nuclear division, cell division, cell--cell signaling, and epithelial cell differentiation. As for the molecular function (MF), DEGs mainly involved in the protein binding, structural molecule activity, and growth factor activity. The cell composition (CC) of DEGs includes cytoplasm, extracellular exosome, nucleoplasm, extracellular space, and extracellular region. In the KEGG pathway analysis found that DEGs significantly enriched in the cytokine receptor interaction, toll‐like receptor signaling pathway, and amoebiasis (Table [2](#mgg31200-tbl-0002){ref-type="table"}, Figure [2](#mgg31200-fig-0002){ref-type="fig"}).

###### 

GO and KEGG pathway enrichment analysis of DEGs

  Term                   Description                               Gene count   *p*‐value
  ---------------------- ----------------------------------------- ------------ -----------
  Biological processes                                                          
  GO:0000082             G1/S transition of mitotic cell           5            3.21E‐04
  GO:0007067             Mitotic nuclear division                  5            8.24E‐03
  GO:0051301             Cell division                             5            2.59E‐02
  GO:0007267             Cell--cell signaling                      4            4.83E‐02
  GO:0030855             Epithelial cell differentiation           4            1.48E‐03
  Cell component                                                                
  GO:0005737             Cytoplasm                                 26           7.75E‐03
  GO:0070062             Extracellular exosome                     22           4.64E‐05
  GO:0005654             Nucleoplasm                               15           3.90E‐02
  GO:0005615             Extracellular space                       14           1.74E‐04
  GO:0005576             Extracellular region                      14           9.73E‐04
  Molecular function                                                            
  GO:0005515             Protein binding                           38           3.88E‐03
  GO:0005198             Structural molecule activity              5            6.99E‐03
  GO:0008083             Growth factor activity                    4            1.36E‐02
  KEGG pathway                                                                   
  hsa04060               Cytokine--cytokine receptor interaction   4            4.08E‐02
  hsa04620               Toll‐like receptor signaling pathway      3            4.45E‐02
  hsa05146               Amoebiasis                                3            4.45E‐02

Abbreviations: DEGs, differentially expressed genes; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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![Gene ontology enrichment analysis. BP, Biological Process; CC, Cellular Components; MF, Molecular Function](MGG3-8-e1200-g002){#mgg31200-fig-0002}

3.3. PPI network construction and analysis {#mgg31200-sec-0015}
------------------------------------------

PPI network of 57 DEGs was constructed in STRING (Figure [3](#mgg31200-fig-0003){ref-type="fig"}), the network visualized by Cytoscape including 42 nodes and 137 edges. The red nodes represent 23 upregulated genes, whereas the blue nodes represent 19 downregulated genes (Figure [4a](#mgg31200-fig-0004){ref-type="fig"}). MOCD plug‐in screened out three key modules, two of which were composed by upregulated genes and one by downregulated genes (Figure [4b‐d](#mgg31200-fig-0004){ref-type="fig"}). The degree ≥10 was used as the screening criteria for the identification of hub genes, and 12 key genes were found to compose the key modules; their names and functions are shown in Table [3](#mgg31200-tbl-0003){ref-type="table"}. We used the cBioportal tool to explore the networks of these hub genes and their coexpressed genes (Figure [4e](#mgg31200-fig-0004){ref-type="fig"}).

![PPI network of 57 DEGs was constructed in STRING. DEGs, Differentially expressed genes](MGG3-8-e1200-g003){#mgg31200-fig-0003}

![PPI network, most significant module of DEGs and Interaction network of the hub genes. (a) PPI network of DEGs was constructed in Cytoscape, red nodes represents upregulated genes, and blue nodes represents downregulated genes. (b--d) There modules were obtained from PPI network using MCODE plug‐in in Cytoscape. (e) Hub genes and their coexpression genes were analyzed by cBioPortal. Nodes with bold black outline mean hub genes. Nodes with thin black outline the coexpression genes. DEGs, differentially expressed genes; MCODE, molecular complex detection; PPI, protein--protein interaction](MGG3-8-e1200-g004){#mgg31200-fig-0004}

###### 

Functional roles of 12 key genes with degree ≥10

  Gene symbol   Full name                                          Function
  ------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ECT2          Epithelial Cell Transforming 2                     ECT2 encodes guanine nucleotide exchange factor, and drives the proliferation and invasion of breast cancer, lung cancer, and gastric cancer.
  WDHD1         WD Repeat And HMG‐Box DNA Binding Protein 1        WDHD1 is the replication initiation factor and involved in the mechanisms of the cancer promotion of E7 genes by evading mitotic checkpoints and inducing polyploid formation
  TYMS          Thymidylate Synthetase                             TYMS encodes thymidine synthase (TS), an important rate‐limiting enzyme that catalyzes the synthesis of pyrimidines, and also a target of fluorouracil medicines.
  FANCI         FA Complementation Group I                         FANCI and FANCD form heterodimers, and participate in DNA repairing and maintain the stability of chromosomes
  CXCL8         C‐X‐C Motif Chemokine Ligand 8                     CXCL8 is a chemotactic factor and induces inflammatory responses, neovascularization, and regulates immune responses
  MCM2          Minichromosome Maintenance Complex Component 2     Participate in the initiation and elongation of DNA replication, form a cocktail of antibodies with TOP2A for cervical lesions
  HELLS         Helicase, Lymphoid Specific                        This gene encodes a lymphoid‐specific helicase. Participates in DNA replication, transcription and repair, and plays a role in cell proliferation
  DTL           Denticleless E3 Ubiquitin Protein Ligase Homolog   DTL is E3 ubiquitin ligase. When DNA is damaged, DTL ubiquitin degrades relevant enzymes to prevent DNA duplication and maintain the stability of genome
  CEP55         Centrosomal Protein 55                             CEP55 is a member of the coiled‐coil protein family. Its main function is anchoring the microtubule polymerization‐related proteins, involving in spindle formation, then regulating cell proliferation.
  CDK1          Cyclin‐Dependent Kinase 1                          Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression
  AURKA         Aurora kinase A                                    AURKA promotes tumor cell proliferation and invasion, which is related to the resistance of chemotherapy and radiosensitivity
  TOP2A         DNA Topoisomerase II Alpha                         TOP2A can control and alter the topologic states of DNA and can be used to identify advanced cervical lesions
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3.4. Key gene analysis {#mgg31200-sec-0016}
----------------------

GEPIA expression analysis showed that these key genes were high expressing in cervical cancer, whereas low expressing in normal cancer tissues, which was consistent with GEO analysis (Figure [5](#mgg31200-fig-0005){ref-type="fig"}). Moreover, overall survival analysis of GEPIA indicated that high expression of *TYMS, MCM2, HELLS,* and *TOP2A* in cervical cancer was correlated with better prognosis. On the other hand, high expression of *CXCL8* in cervical cancer tumor tissues is associated with poor prognosis of patients (Figure [6](#mgg31200-fig-0006){ref-type="fig"}). *CXCL8* expression in various tissues from UCLCAN database showed that CXCL8 upregulated in multiple tumor types including Colorectal cancer, cervical cancer, Esophageal cancer, Head and neck cancer, and so on (Figure [7a](#mgg31200-fig-0007){ref-type="fig"}). The DEGs between cervical cancer and normal tissues from four datasets analyzed by Oncomine showed that *CXCL8* had high expression level (Figure [7b](#mgg31200-fig-0007){ref-type="fig"}). Clinical immunohistochemistry samples of patients with cervical cancer were inquired through HPA database. Compared with normal tissues, *CXCL8* protein was highly expressed in patients with cervical cancer (Figure [7c](#mgg31200-fig-0007){ref-type="fig"}).

![Expression boxplots of key genes using GEPIA website. ECT2, WDHD1, TYMS, FANCI, CXCL8, MCM2, HELLS, DTL, CEP55, CDK1, AURKA, and TOP2A were significantly upregulated in cervical cancer compared with normal tissues (*p* \< .01). GEPIA, Gene Expression Profiling Interactive Analysis; ECT2: NC_000003.12; WDHD1: NC_000014.9; TYMS: NC_000018.10; FANCI: NC_000015.10; CXCL8: NC_00 0004.12; MCM2: NC_000003.12; HELLS: NC_000010.11; DTL:NC_000001.11; CEP55: NC_000010.11; CDK1: NC_000010.11; AURKA:NC_000020.11](MGG3-8-e1200-g005){#mgg31200-fig-0005}

![Survival analysis. Expression level of CXCL8, HELLS, MCM2, TYMS, and TOP2A was significantly related to the overall survival of patients with cervical squamous cancer (*p* \< .05)](MGG3-8-e1200-g006){#mgg31200-fig-0006}

![Expression profiles in human cancers, analysis comparison, and protein expression of CXCL8. (a) Expression profiles in human cancers of CXCL8 were analyzed by UALCAN. (b) The expression of the CXCL8 was compared during the four datasets. Normal tissues as control group. Values above the average were deemed to be overexpressed hub genes (red). (c) Immunohistochemistry results from human protein atlas database showed CXCL8 protein was upregulated](MGG3-8-e1200-g007){#mgg31200-fig-0007}

4. DISCUSSION {#mgg31200-sec-0017}
=============

As we all know, the morbidity and mortality of cervical cancer are high in female. Although the chemoradiotherapy and surgery might cure early‐stage patients, many patients suffered from the recurrence and metastasis. And it is still unsatisfied of the effect of treatment to recurrence. Previous studies reported that some molecules and pathways involved in the HPV‐related and the non--HPV‐related cervical cancer. However, the molecule pathway is still needed to be explored.

Among 12 key genes we screened, *CXCL8*, with degree of 11 involved in all KEGG pathways and correlated with the prognosis of cervical cancer, was thought to be more relevant to cervical cancer. *CXCL8*, also known as interleukin 8 (*IL‐8*), is a pleiotropic chemokine. *CXCL8* binds to its chemokine receptor CXCR1/2, and induces inflammatory responses, neovascularization, and regulates immune responses. Multiple studies have shown that CXCL8/ cxcr1/2 axis was highly expressed in lung cancer, malignant melanoma, breast cancer, colorectal cancer, osteosarcoma, pancreatic cancer, and other cancers. It plays an important role in regulating tumor growth, invasion, angiogenesis, and resistance through antiapoptosis, cell signal transduction, and immune evasion. *CXCL8* could regulate VEGFR, matrix metalloprotein (MMP), and other mediators through autocrine and paracrine pathways to induce tumor angiogenesis (Kumar, Cherukumilli, Mahmoudpour, Brand, & Bandapalli, [2018](#mgg31200-bib-0027){ref-type="ref"}). And, *CXCL8* involves in the mechanisms of resistance to the apoptosis, thus induces tumorogenesis (Xiao et al., [2015](#mgg31200-bib-0057){ref-type="ref"}). In addition, Epithelial mesenchymal transformation (EMT) modifies the tumor microenvironments resulting in tumor cells endowed with stem cell characteristics, immune escape, proliferation, and migration, and *CXCL8* is conducive to the formation of EMT (Geng et al., [2019](#mgg31200-bib-0018){ref-type="ref"}; Visciano et al., [2015](#mgg31200-bib-0055){ref-type="ref"}). Multiple studies suggested that *CXCL8* promotes pulmonary metastasis of osteosarcoma (Gross et al., [2018](#mgg31200-bib-0019){ref-type="ref"}), is the prognosis marker of pancreatic cancer (Litman‐Zawadzka, Lukaszewicz‐Zajac, Gryko, Kulczynska‐Przybik, & Mroczko, [2018](#mgg31200-bib-0030){ref-type="ref"}), and malignant melanoma (Ugurel, Rappl, Tilgen, & Reinhold, [2001](#mgg31200-bib-0050){ref-type="ref"}) is the recurrence marker of breast cancer (Khazali, Clark, & Wells, [2018](#mgg31200-bib-0024){ref-type="ref"}). Moreover, *CXCL8* is highly expressed in colorectal cancer, and negatively correlated with overall and disease‐free survival (Xiao et al., [2015](#mgg31200-bib-0057){ref-type="ref"}). *CXCL8* has also been reported to play an important role in chemotherapy resistance, antivascular‐targeted therapy, and immunotherapy of tumors. *CXCL8* can induce the accumulation of myeloid‐derived suppressor cells (MDSCs), which downregulate the immune activity to tumor cells by inhibiting T cells (Mabuchi, Yokoi, Komura, & Kimura, [2018](#mgg31200-bib-0033){ref-type="ref"}; Shi et al., [2018](#mgg31200-bib-0043){ref-type="ref"}). Sanmamed MF et al (Sanmamed et al., [2017](#mgg31200-bib-0040){ref-type="ref"}) showed that the decrease in baseline level of *CXCL8* could predict the better efficacy of anti--pd‐1 treatment in lung cancer and melanoma, and better overall survival, and the pseudo progress of immunotherapy. On the other hand, *CXCL8* works in combination with its cognate receptors cxcr1/2. SINGH S et al (Fields & Justilien, [2010](#mgg31200-bib-0014){ref-type="ref"}; Varney et al., [2011](#mgg31200-bib-0054){ref-type="ref"}) found that CXCR1 and CXCR2 inhibitors could inhibit the liver metastasis of colon cancer, and the growth of melanoma in mice tumor model. The combination of CXCR1 inhibitors Reparixin and paclitaxel inhibits breast cancer stem cells (CSC) to suppress the brain metastases from breast cancer model (Brandolini et al., [2015](#mgg31200-bib-0005){ref-type="ref"}), and the first relevant clinical trial is currently underway (NCT02370238) in breast cancer. Lin et al. ([2019](#mgg31200-bib-0029){ref-type="ref"}) indicate that Reparixin can suppress PD‐L1 expression, and improve tumor immune microenvironment. Although the above studies prove the importance of CXCL8 in a variety of tumors, the research and evidence of *CXCL8* in cervical cancer still needed to be explored. Our bioinformatics study showed that *CXCL8* is a key gene for the carcinogenesis of cervical cancer, and its expression increased in cervical cancer, and might be a marker of poor prognosis. This conclusion shown in Figure [7](#mgg31200-fig-0007){ref-type="fig"} has been verified in different databases such as oncomine and UCLCAN. TCGA is the largest cancer gene information database with reliable data sources so that GEPIA using data from TCGA may make the results more reliable. In addition, more basic and clinical studies needed to confirm this conclusion, we could further explore the application of *CXCL8*/ CXCR1/2 axis inhibitors in the treatment of cervical cancer.

*TYMS* encodes thymidine synthase (TS), an important rate‐limiting enzyme that catalyzes the synthesis of pyrimidines, is important for DNA synthesis and repair, and also a target o[f]{.ul} fluorouracil medicines. Multiple studies have shown that the expression level of *TYMS* may be related to the sensitivity of radiotherapy and chemotherapy for cervical cancer (Saga et al., [2002](#mgg31200-bib-0038){ref-type="ref"}, [2003](#mgg31200-bib-0039){ref-type="ref"}). Suzuki, Tsukagoshi, Saga, Ohwada, and Sato ([1999](#mgg31200-bib-0045){ref-type="ref"}) compared the immunohistochemical level of TS and the survival of 66 patients with stage IIIb cervical cancer, showing that the 5‐year survival rate with high and low level of TS was 36.8% and 87.2%, respectively. Therefore, high TS may be associated with poor prognosis of cervical cancer. As for the other two factors, both *TOP2A* and *MCM2* regulate cells in S phase. Studies have indicated that *TOP2A* and *MCM2* involved in the occurrence and development of cervical cancer, and the increased expression of them could be viewed as diagnostic markers of cervical cancer (Peres et al., [2016](#mgg31200-bib-0035){ref-type="ref"}; Zheng, [2015](#mgg31200-bib-0060){ref-type="ref"}). ProExC, a cocktail of antibodies developed by becton‐dickinson for *TOP2A* and *MCM2*, can be used to identify advanced cervical lesions (Dixon et al., [2017](#mgg31200-bib-0012){ref-type="ref"}; Tosuner et al., [2017](#mgg31200-bib-0049){ref-type="ref"}). Our analysis results showed that the expression levels of *TYMS*, *MCM2*, *HELLS*, and *TOP2A* in cervical cancer increased and positively correlated with the prognosis of cervical cancer. Previous studies have shown that *MCM2* and *TOP2A* may be markers for screening of precancerous lesions and cervical cancer, whereas others believe that the expression level of *MCM2* cannot predict tumor stage and posttreatment response (Amaro Filho et al., [2014](#mgg31200-bib-0002){ref-type="ref"}; Kuku et al., [2015](#mgg31200-bib-0026){ref-type="ref"}). And few studies have followed patients, and analyzed their survival and prognosis. Thus, our findings may help answer this question. At present, the relevant mechanisms and pathways have not been clearly defined. We consider that in addition to the influence on other genes, they may also play a role in posttranslational modification or activation of other pathways, and ultimately lead to prolonged survival of patients, which needs further research and exploration.

The E6/E7 gene is thought to be involved in tumorigenesis in cells infected with high‐risk HPV. Studies suggest that *CDK1* and *WDHD1* involved in the mechanisms of the cancer promotion of E6 and E7 genes by evading mitotic checkpoints and inducing polyploid formation, thus resulted in gene instability and cervical cancer (Zhang et al., [2015](#mgg31200-bib-0058){ref-type="ref"}; Zhou et al., [2016](#mgg31200-bib-0061){ref-type="ref"}). *AURKA* is associated with centrosomal expansion, spindle and chromosomal instability, and its high expression promotes tumor cell proliferation and invasion (Zhang, Wang, Liu, Hua, & Xin, [2009](#mgg31200-bib-0059){ref-type="ref"}). The researchers (Sun et al., [2015](#mgg31200-bib-0044){ref-type="ref"}) (Ma et al., [2017](#mgg31200-bib-0032){ref-type="ref"}) found that *AURKA* is related to the resistance of taxol and radiosensitivity. Currently, *AUARK* inhibitors are being explored as molecular‐targeted medicines for the treatment of cervical cancer (Gabrielli et al., [2015](#mgg31200-bib-0015){ref-type="ref"}; Umene et al., [2013](#mgg31200-bib-0052){ref-type="ref"}). All the above molecules have been proved to play an important role in the occurrence and development of cervical cancer.

Although the other genes, we got by the bioinformatic analysis, have not been found to work in the occurrence and development of cervical cancer, they are still proved to be involved in the carcinogenesis and progression in tumor. *ECT2* encodes guanine nucleotide exchange factor, and drives the proliferation and invasion of breast cancer, lung cancer, and gastric cancer. *FANCI* and *FANCD* form heterodimers, and participate in DNA repairing (van Twest et al., [2017](#mgg31200-bib-0053){ref-type="ref"}). However, HPV virus might damage this repair mechanism, leading to the occurrence of tumors and resistance to chemotherapy (Khanal & Galloway, [2019](#mgg31200-bib-0023){ref-type="ref"}). *DTL* is involved in cell cycle regulation, and when DNA is damaged, it can stop replication and maintain gene stability (Abbas & Dutta, [2011](#mgg31200-bib-0001){ref-type="ref"}). *HELLS* encodes a lymphoid‐specific helicase that involved in DNA replication, transcription, and repair during cell proliferation (Geiman, Durum, & Muegge, [1998](#mgg31200-bib-0017){ref-type="ref"}). Increased expression of *HELLS* is detected in various malignant tumors, such as head and neck squamous cell carcinoma, melanoma, and kidney cancer (Chen et al., [2017](#mgg31200-bib-0010){ref-type="ref"}; Kim, Symanowski, Samlowski, Gonzales, & Ryu, [2010](#mgg31200-bib-0025){ref-type="ref"}; Waseem, Ali, Odell, Fortune, & Teh, [2010](#mgg31200-bib-0056){ref-type="ref"}). Through our screening methods, we obtained these genes, and the mechanisms of them in cervical cancer deserve further exploration.

To sum up, we utilized the public online database, and bioinformatics analysis tools to successfully identified 57 DEGs in cervical cancer. Among these, 12 genes may be biomarker of cervical cancer, of which five genes (TYMS, TOP2A, MCM2, HELLS, and CXCL8.) are related to occurrence and prognosis. These results indicated that our methods are meaningful to screen the key genes by using the public database and tools. On the other hand, some genes related to cervical cancer have been estimated by our analysis, and more experiments are needed to explore these genes.
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